HIF prolyl-hydroxylase inhibitor

we may need to consider a different type of medication.

There's another class of treatment called HIF-PHIs.

It works through a different pathway than ESAs to help your body produce more erythropoietin.

We talked before about that being a main cause of anemia in people with dialysis.

You would take it daily along with your other medications.

Now, I do want to be upfront with you about the risks because that's important.

Just like with ESAs, HIF-PHIs carry an FDA warning of increased risk of serious events like heart attack, blood clots, stroke.

These are real risks that we take seriously.

And previously, we've only really had access to things like darbopoietin and recombinant human erythropoietin, which we know have been really significantly associated with the production of anti-erythropoietin antibodies, particularly for recombinant human erythropoietin.

But now we've got the HIF inhibitors and these HIF inhibitors work by essentially mimicking hypoxia in the body so that there is stimulation of erythropoietin production.

And we've now got several studies where cats with chronic kidney disease have been giving myelodustat and they've demonstrated a significant increase in their PCV.

And we've included protocols in the guidelines about dosages, how to monitor the cats when you're giving this medication.